1. Home
  2. SGBX vs ENTO Comparison

SGBX vs ENTO Comparison

Compare SGBX & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGBX
  • ENTO
  • Stock Information
  • Founded
  • SGBX 2007
  • ENTO 2014
  • Country
  • SGBX United States
  • ENTO United States
  • Employees
  • SGBX N/A
  • ENTO 2
  • Industry
  • SGBX RETAIL: Building Materials
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SGBX Consumer Discretionary
  • ENTO Health Care
  • Exchange
  • SGBX Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • SGBX 2.4M
  • ENTO 1.7M
  • IPO Year
  • SGBX 2017
  • ENTO 2016
  • Fundamental
  • Price
  • SGBX $0.41
  • ENTO $0.36
  • Analyst Decision
  • SGBX
  • ENTO
  • Analyst Count
  • SGBX 0
  • ENTO 0
  • Target Price
  • SGBX N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • SGBX 227.6K
  • ENTO 1.4M
  • Earning Date
  • SGBX 05-16-2025
  • ENTO 05-20-2025
  • Dividend Yield
  • SGBX N/A
  • ENTO N/A
  • EPS Growth
  • SGBX N/A
  • ENTO N/A
  • EPS
  • SGBX N/A
  • ENTO N/A
  • Revenue
  • SGBX $4,976,618.00
  • ENTO N/A
  • Revenue This Year
  • SGBX $1,628.82
  • ENTO N/A
  • Revenue Next Year
  • SGBX N/A
  • ENTO N/A
  • P/E Ratio
  • SGBX N/A
  • ENTO N/A
  • Revenue Growth
  • SGBX N/A
  • ENTO N/A
  • 52 Week Low
  • SGBX $0.30
  • ENTO $0.19
  • 52 Week High
  • SGBX $9.30
  • ENTO $3.24
  • Technical
  • Relative Strength Index (RSI)
  • SGBX 47.75
  • ENTO 38.33
  • Support Level
  • SGBX $0.34
  • ENTO $0.38
  • Resistance Level
  • SGBX $0.39
  • ENTO $0.39
  • Average True Range (ATR)
  • SGBX 0.04
  • ENTO 0.04
  • MACD
  • SGBX 0.01
  • ENTO -0.00
  • Stochastic Oscillator
  • SGBX 81.85
  • ENTO 18.24

About SGBX Safe & Green Holdings Corp.

Safe & Green Holdings Corp is a modular solutions company. The company currently provides modules made out of both code-engineered cargo shipping containers and wood for use as both permanent or temporary structures for residential housing use and commercial use, including for health care facilities. It operates in four segments: construction services; medical; real estate development; and environmental. The company generates the majority of its revenue from the Construction segment includes the company's manufacturing unit SG ECHO and other modules projects.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: